- 英文名称
- Mozavaptan Hydrochloride
- 分子式
- C27H30ClN3O2
- 分子量
- 464
- 中文别名
- N-(4-(5-(二甲氨基)-2,3,4,5-四氢-1H-苯并[b]氮杂环庚烷-1-羰基)苯基)-2-甲基苯甲酰胺盐酸盐; 5-(二甲基氨基)-1-[4-(2-甲基苯甲酰胺基)苯甲酰]-2,3,4,5-四氢-1H-苯并氮杂卓盐酸盐; 盐酸莫扎伐普坦; N-(4-(5-(Dimethylamino)-2,3,4,5-tetrahydro-1H-benzo[b]azepine-1-carbonyl)phenyl)-2-methylbenzamide hydrochloride; N-[4-[5-(dimethylamino)-2,3,4,5-tetrahydro-1-benzazepine-1-carbonyl]phenyl]-2-methylbenzamide,hydrochloride; Benzamide, N-[4-[[5-(dimethylamino)-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl]carbonyl]phenyl]-2-methyl-, hydrochloride (1:1); N-(4-{[5-(Dimethylamino)-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl]carbonyl}phenyl)-2-methylbenzamide hydrochloride (1:1); Physuline; Mozavaptane hydrochloride; Mozavaptan HCl; 5-(Dimethylamino)-1-[4-(2-methylbenzamido)benzoyl]-2,3,4,5-tetrahydro-1H-benzazepine hydrochloride; OPC 31260 hydrochloride
- 用途
- 作为一种苯并氮杂卓衍生物，是有效、选择性、竞争性和口服活性的加压素V2受体拮抗剂，IC50为14 nM，对V2受体选择性比V1受体高约85倍，可用于低钠血症、抗利尿激素不适当综合征(SIADH)和充血性心力衰竭的研究；体内外研究显示其能拮抗精氨酸加压素的抗利尿作用，口服给药可剂量依赖性增加尿量并降低尿渗透压。
